Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	29.31B
Revenue (ttm)	13.13B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.42
PE Ratio	13.07
Forward PE	n/a
Dividend	1.48 (5.86%)
Ex-Dividend Date	Jul 8, 2024

Volume	622,105
Average Volume	680,337
Open	25.30
Previous Close	25.30
Day's Range	25.05 - 25.75
52-Week Range	23.10 - 34.00
Beta	0.28
RSI	41.45
Earnings Date	Mar 27, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,933
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2023, HKG:1513's revenue was 12.43 billion, a decrease of -1.58% compared to the previous year's 12.63 billion. Earnings were 1.95 billion, an increase of 2.32%.

Financial numbers in CNY